Woodline Partners LP Purchases 57,077 Shares of Abbott Laboratories $ABT

Woodline Partners LP boosted its position in Abbott Laboratories (NYSE:ABT) by 107.7% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 110,092 shares of the healthcare product maker’s stock after acquiring an additional 57,077 shares during the period. Woodline Partners LP’s holdings in Abbott Laboratories were worth $14,604,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Zurich Insurance Group Ltd FI increased its position in shares of Abbott Laboratories by 5,771.1% during the first quarter. Zurich Insurance Group Ltd FI now owns 1,115,514 shares of the healthcare product maker’s stock valued at $147,973,000 after buying an additional 1,096,514 shares during the period. American Trust increased its position in shares of Abbott Laboratories by 0.3% during the first quarter. American Trust now owns 30,753 shares of the healthcare product maker’s stock valued at $4,079,000 after buying an additional 92 shares during the period. Empowered Funds LLC grew its holdings in shares of Abbott Laboratories by 4.7% during the first quarter. Empowered Funds LLC now owns 50,724 shares of the healthcare product maker’s stock worth $6,729,000 after purchasing an additional 2,266 shares in the last quarter. MBB Public Markets I LLC purchased a new position in shares of Abbott Laboratories during the first quarter worth about $332,000. Finally, Ascent Group LLC grew its holdings in shares of Abbott Laboratories by 71.6% during the first quarter. Ascent Group LLC now owns 32,279 shares of the healthcare product maker’s stock worth $4,282,000 after purchasing an additional 13,467 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.46% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently commented on ABT. Wells Fargo & Company cut their price objective on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a report on Friday, July 18th. Mizuho boosted their price objective on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, July 16th. Leerink Partners began coverage on Abbott Laboratories in a research note on Monday, June 16th. They issued a “market perform” rating and a $143.00 target price for the company. Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Finally, Morgan Stanley upped their target price on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $144.47.

Abbott Laboratories Stock Down 1.9%

Shares of Abbott Laboratories stock opened at $129.39 on Thursday. The company’s 50 day moving average price is $130.43 and its 200-day moving average price is $131.35. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The stock has a market capitalization of $225.20 billion, a price-to-earnings ratio of 16.21, a P/E/G ratio of 2.50 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. The business had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were given a dividend of $0.59 per share. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.